奥姆尼艾比生物
OABI
4.59
-0.14
-2.96%
奥姆尼艾比生物
US · OABI
#3556 按市值排名
上市于 2021
4.59
-0.14
-2.96%
实时 - 追踪5344个代码 - 心跳于266秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例下降了0.1个百分点。
机构持股
- 机构持股比例
- 47.45% -0.12pp
- 机构数量
- 171 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund23.55%
Hedge Fund16.85%
Individual/Insider11.62%
Public Company3.92%
VC/PE Fund2.70%
Insurance Company0.14%
Family Office/Trust0.13%
Private Company0.12%
Other40.93%
主要股东 截至 2026-06-30
Whitefort Capital Management, LP
7.05% · 10.25M 股
BlackRock
6.12% · 8.90M 股
Robert Goldstein
5.20% · 7.56M 股
Nomura Holdings, Inc.
3.46% · 5.03M 股
Gotham Asset Management, LLC
3.26% · 4.73M 股
Vanguard Capital Management, LLC
3.17% · 4.61M 股
Cadian Capital Management, LP
2.90% · 4.21M 股
Matthew Foehr
2.77% · 4.03M 股
Avista Capital Holdings, L.P.
2.70% · 3.92M 股
John Higgins
2.04% · 2.96M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 37次买入 · 13次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Matthew Foehr | Chief Executive Officer | 2.77% |
| John Higgins | Chairperson | 2.04% |
| Charles Berkman | Chief Legal Officer | 0.20% |
| Kurt Gustafson | Chief Financial Officer | 0.13% |
| Jennifer Cochran | Independent Director | 0.12% |
| Carolyn Bertozzi | Independent Director | 0.08% |
| Steven Love | Independent Director | 0.06% |
| Philip Gotwals | Director | 0.02% |
| Steven Crouse | Director | 0.02% |
| Amechi Nwachuku | Executive VP & Chief Operating Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-31 | Amechi Nwachuku | Executive VP & Chief Operating Officer | Other Derivative Acquisition | +800,000 | $1.98 |
| 2026-06-16 | John Higgins | Chairperson | Other Derivative Acquisition | +20,000 | -- |
| 2026-06-16 | John Higgins | Chairperson | Other Derivative Acquisition | +40,000 | $2.03 |
| 2026-06-16 | John Higgins | Chairperson | Derivative Exercise and Retained | +20,000 | -- |
| 2026-06-16 | Carolyn Bertozzi | Independent Director | Other Derivative Acquisition | +20,000 | -- |
| 2026-06-16 | Carolyn Bertozzi | Independent Director | Other Derivative Acquisition | +40,000 | $2.03 |
| 2026-06-16 | Carolyn Bertozzi | Independent Director | Derivative Exercise and Retained | +20,000 | -- |
| 2026-06-16 | Steven Love | Independent Director | Other Derivative Acquisition | +20,000 | -- |
| 2026-06-16 | Steven Love | Independent Director | Other Derivative Acquisition | +40,000 | $2.03 |
| 2026-06-16 | Steven Love | Independent Director | Derivative Exercise and Retained | +20,000 | -- |
| 2026-06-16 | Philip Gotwals | Director | Other Derivative Acquisition | +20,000 | -- |
| 2026-06-16 | Philip Gotwals | Director | Other Derivative Acquisition | +40,000 | $2.03 |
| 2026-06-16 | Philip Gotwals | Director | Derivative Exercise and Retained | +20,000 | -- |
| 2026-06-16 | Steven Crouse | Director | Other Derivative Acquisition | +20,000 | -- |
| 2026-06-16 | Steven Crouse | Director | Other Derivative Acquisition | +40,000 | $2.03 |
| 2026-06-16 | Steven Crouse | Director | Derivative Exercise and Retained | +20,000 | -- |
| 2026-06-16 | Jennifer Cochran | Independent Director | Other Derivative Acquisition | +20,000 | -- |
| 2026-06-16 | Jennifer Cochran | Independent Director | Other Derivative Acquisition | +40,000 | $2.03 |
| 2026-06-16 | Jennifer Cochran | Independent Director | Derivative Exercise and Retained | +20,000 | -- |
| 2026-04-20 | Philip Gotwals | Director | Derivative Exercise and Retained | +13,333 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:09 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奥姆尼艾比生物 讨论区 0 条评论